One of the main features of Alzheimer’s is the agitation and aggressive behavior produced in patients by the difficulty in managing their confused emotions. The wellness of such patients and their caregivers depends on finding an appropriate treatment to minimize this conflicting situation.
Pharmacological treatment of this disorder includes anxiolytics, antipsychotics, and, in the most severe cases, anticonvulsants, with their consequent adverse effects.
Some cannabinoids such as THC and CBD have been used on occasion, but because of their current legal and social status, such products are difficult to obtain in an appropriate form.
Landsteiner Genmed is currently developing an oral cannabinoid formulation whose efficacy, rapid absorption, and lack of adverse effects make it especially indicated to control the aforementioned disorders.